地舒单抗需要注意什么事项？

On May 28, 2010, the European Commission approved the treatment of bone loss associated with hormone suppression in postmenopausal women with osteoporosis and prostate cancer. It can also be used in patients for whom other current treatments are ineffective or intolerable to reduce the risk of fractures. For the first time, denosumab was approved in 27 EU member states, as well as Norway, Iceland, and Liechtenstein. In June of the same year, denosumab was approved by the FDA for marketing. 

While using denosumab, many patients pay more attention to its effects and usage and dosage, but ignore the precautions. However, if some precautions are not taken seriously, they will not only affect the treatment effect, but even cause serious harm to the patients themselves.

Precautions for denosumab:

1. Hypocalcemia must be corrected before denosumab treatment is started. For patients who are prone to hypocalcemia and mineral metabolism imbalance (such as those with a history of hypoparathyroidism, thyroid surgery, parathyroid surgery, malnutrition, small bowel resection, severe renal insufficiency), clinical monitoring of creatinine and mineral levels is required, and such patients should be instructed to pay attention to the symptoms of hypocalcemia and to supplement adequate amounts of calcium and vitamin D. 

2. Patients who are concurrently taking immunosuppressants or have compromised immune systems may have an increased risk of serious infections. Physicians must fully consider the benefit-risk ratio before prescribing denosumab to such patients. Physicians should evaluate the need to continue denosumab therapy in patients who develop serious infections while taking denosumab. 

3. Osteonecrosis of the mandible usually occurs with tooth extraction and local infection that delays healing. A routine oral examination should be performed before starting denosumab treatment, and good oral hygiene should be maintained after treatment is started. If a patient develops osteonecrosis of the jaw, treatment for osteonecrosis of the jaw may worsen the condition, and discontinuation of the medication should be considered at this time. 

4. If the patient suffers from other diseases, he or she should inform the doctor in advance. People with allergies and hypocalcemia are prohibited from using this product.